Okogen, Inc., a clinical-stage biotechnology company developing a host-directed antiviral platform, has dosed the first patient in the EMERALD Trial, its multicenter Phase 1/2 clinical study evaluating Treyegen™ (OKG-0303) for acute infectious conjunctivitis. The first dosing occurred at Ambade Eye Hospital in Nagpur, India, according to the company’s announcement.
The milestone matters because acute infectious conjunctivitis—commonly known as pink eye—is frequently treated without knowing whether the underlying cause is viral or bacterial. Treyegen is being developed as a single investigational ophthalmic therapy that combines antiviral, antibacterial, and symptom-relieving mechanisms, potentially offering a unified approach where the cause is often unknown at diagnosis. If successful, this could reduce the guesswork in treatment and help curb inappropriate antibiotic use.
The EMERALD Trial will assess safety, tolerability, clinical outcomes, and viral and bacterial activity. Beyond the immediate indication, the study is designed to support the advancement of Okogen’s broader ranpirnase platform across multiple therapeutic areas. The company’s strategy positions ophthalmology as the lead clinical proving ground for the platform, with the goal of applying clinical insights, formulation expertise, and manufacturing capabilities across a broader portfolio of antiviral therapies.
For investors and the biotech sector, the first patient dosing is a tangible sign of clinical progress for a platform that extends well beyond eye infections. Okogen is advancing ranpirnase-based therapies across four therapeutic pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. A successful ophthalmology program could therefore serve as validation for the platform’s broader potential and accelerate development in other areas.
Full details of the announcement, including downloadable images and bios, are available via the company’s click here. More information about Okogen and its pipeline can be found at www.okogen.com.
As with any clinical-stage program, the company notes that forward-looking statements about Treyegen and the ranpirnase platform are subject to risks and uncertainties, including those related to clinical enrollment, study outcomes, regulatory requirements, manufacturing, and financing. Actual results may differ materially.
